• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

    5/19/25 4:05:00 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $OCX alert in real time by email
    • New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunity
    • Brings pricing in line with existing competitive technology
    • Expands market appeal for prospective FDA-cleared kitted product at transplant centers

    IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the company's position in the growing transplant rejection testing market and suggests potential upside to its estimated $1 billion total addressable market.

    The Centers for Medicare & Medicaid Services (CMS) has improved its reimbursement rate to $2,753 per result. This represents an increase from the prior structure using an earlier version of the assay, which paid $2,222 for first-time testing of a patient and $1,029 for subsequent tests. GraftAssureCore1 is Oncocyte's lab-developed test (LDT), which is run at the company's CLIA-certified Nashville lab2.

    "Over the past two years Oncocyte has made significant investments in improving the scalability and manufacturability of our workflow to support our kitted test program," said CEO, Josh Riggs. "Last fall, we transferred these improvements into our CLIA lab and submitted to MolDX3 for repricing. We are very pleased with the result."

    The new rate for the optimized workflow sets a benchmark that can be used to establish a reimbursement pathway for its future kitted test, GraftAssureDx, which the company expects to submit for FDA review by the end of this year. This process, known as "bridging," would allow other labs, upon receipt of FDA marketing authorization by Oncocyte, to purchase the Oncocyte kits to perform the test themselves and bill Medicare at the same rate.

    "We believe this new price reflects the value that our technology brings to the transplant community," continued Mr. Riggs. "Once we receive FDA authorization, the ability to run the test clinically and bill Medicare directly will drive much broader adoption of our technology. We look forward to providing transplant centers the opportunity to access a high-quality, FDA-cleared kit with established reimbursement."

    "We are very excited about the future of our company and this technology," said Chief Science Officer Dr. Ekke Schuetz. "We believe that our activation of decentralized testing will enable broader use of dd-cfDNA, transforming it from a high-cost technology to a revenue generating solution for transplant institutions."

    Oncocyte provided a positive update on its FDA submission process and clinical trial in an announcement on April 30. The company noted that a Central Institutional Review Board approved its clinical trial, that final preparatory steps are underway at the first participating transplant centers, that it expects three of the top 10 U.S. transplant centers to participate in its trial, and that nearly 10% of annual U.S. transplant volume is represented in clinical trial site interest.

    Footnotes:

    (1) Oncocyte's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company's scientists in Germany and the U.S. have played a critical role over the past decade in developing the science that helped establish dd-cfDNA as a trusted biomarker of transplant rejection, and the company is now commercializing that technology using a market disruptive approach. Per recent rebranding announcements, GraftAssure is becoming the umbrella brand for the company's dd-cfDNA test portfolio. The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. For purposes of this press release, references to "GraftAssureCore" shall be deemed to include the test previously marketed as VitaGraft. The company is also in the process of rebranding its research-use-only (RUO) test kit, GraftAssure, as "GraftAssureIQ," and rebranding its future in-vitro diagnostic (IVD) test kit as "GraftAssureDx."

    (2) CLIA, or the Clinical Laboratory Improvement Amendments, is a federal program overseen by CMS that ensures laboratories meet quality standards when performing diagnostic testing on human samples.

    (3) MolDX is a program managed by Medicare contractor Palmetto GBA (Government Benefits Administrators) that reviews molecular diagnostic tests and decides whether they should be covered and reimbursed by Medicare.

    About Oncocyte

    Oncocyte is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.oncocyte.com/ for more information.

    GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Oncocyte Corp.

    Forward-Looking Statements

    Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, Oncocyte's commercial progress, anticipated FDA submissions, the expectation that Oncocyte will receive FDA marketing authorization for GraftAssureDx, the belief that decentralized testing will enable broader use of dd-cfDNA, transforming it from a high-cost technology to a revenue generating solution for transplant institutions, the expectation that three of the top 10 U.S. transplant centers will participate in Oncocyte's trial, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors" and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. 

    Investor Contact:

    Doug Farrell

    LifeSci Advisors LLC

    [email protected]



    Primary Logo

    Get the next $OCX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OCX

    DatePrice TargetRatingAnalyst
    3/28/2025$5.00Buy
    Lake Street
    5/24/2022Overweight → Equal-Weight
    Stephens
    3/14/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    3/11/2022$11.00 → $6.00Buy
    Lake Street
    3/11/2022$5.00 → $4.00Buy
    Needham
    1/7/2022$3.10Overweight
    Stephens & Co.
    1/6/2022$3.10Overweight
    Piper Sandler
    12/16/2021$7.00 → $5.00Buy
    Needham
    More analyst ratings

    $OCX
    SEC Filings

    See more
    • Oncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)

      7/2/25 5:01:52 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Oncocyte Corp (0001642380) (Filer)

      6/17/25 7:33:46 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEFA14A filed by Oncocyte Corporation

      DEFA14A - Oncocyte Corp (0001642380) (Filer)

      5/14/25 5:08:11 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 7:00:32 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 5:00:15 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/10/25 8:43:04 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Arno Andrew was granted 55,000 shares, increasing direct ownership by 67% to 136,554 units (SEC Form 4)

      4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

      7/3/25 4:05:25 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Silverman Lou was granted 35,000 shares, increasing direct ownership by 2,238% to 36,564 units (SEC Form 4)

      4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

      7/3/25 4:05:34 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Last Andrew J. was granted 35,000 shares, increasing direct ownership by 776% to 39,509 units (SEC Form 4)

      4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

      7/3/25 4:05:22 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

      New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. ("iMDx" or the "Company"), (NASDAQ:IMDX), formerly known as Oncocyte Corporation (NASDAQ:OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company's common stock, listed on the Nasdaq Capital Market, will begin trading

      6/17/25 7:00:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

      New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the company's position in the growing transplant rejection testing market and suggests potential upside to its estimated $1 billion total addressable market. The Centers for

      5/19/25 4:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Reports Q1 2025 Results and Business Progress

      Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are now using our GraftAssure research-use-only kitsTo reflect our larger market opportunity, we plan to rename the company in Q2 IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter results: Fellow Shareholders,We're off to a fast and intensely focused start in 2025. Just two months ago, we shared our strategic outlook — and sin

      5/12/25 4:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OncoCyte with a new price target

      Lake Street initiated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00

      3/28/25 8:35:58 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • OncoCyte downgraded by Stephens

      Stephens downgraded OncoCyte from Overweight to Equal-Weight

      5/24/22 8:51:33 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • OncoCyte downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded OncoCyte from Overweight to Sector Weight

      3/14/22 7:21:22 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Financials

    Live finance-specific insights

    See more
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $OCX
    Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

      Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. In this part-time role, he will support a range of strategic and clinical goals for Oncocyte. Dr. Billings is a recognized pioneer in genomics and precision medicine with over 40 years of experience spanning academia, government,

      1/8/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

      NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (NASDAQ:OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025. Under the leadership of CEO Josh Riggs, Oncocyte is poised for a transformative period with its upcoming commercial launches. The company's flagship products, the VitaGraft™ Kidney diagnostic test and its research use only (RUO) GraftAssure

      6/24/24 12:41:19 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      12/9/24 5:30:06 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Oncocyte Corporation

      SC 13G - Oncocyte Corp (0001642380) (Subject)

      11/14/24 1:26:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      10/24/24 12:13:28 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care